Nilotinib Hydrochloride Monohydrate

DRUG3 trials

Sponsors

Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI)

Conditions

Advanced Malignant Solid NeoplasmAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8

Phase 1

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

CompletedNCT04205903

Ohio State University Comprehensive Cancer CenterAnatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 +17

Start: 2020-12-11End: 2024-12-18Updated: 2025-06-29

Phase 2

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Active, not recruitingNCT05554341

National Cancer Institute (NCI)Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm

Start: 2023-07-14End: 2026-06-30Target: 40Updated: 2026-04-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RecruitingNCT05564377

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 +12

Start: 2023-04-07End: 2030-07-01Target: 2900Updated: 2026-04-03

Related Papers

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.

Journal of Clinical Oncology2020-05-202 citations